Key result
Cardiometabolic multimorbidity is linked to ~40% higher late-life depression risk per additional condition.
Why the study?
Late-life depression frequently co-exists with cardiometabolic multimorbidity, triggering accelerated biological aging and increased mortality.
Late-life depression in the context of cardiometabolic multimorbidity constitutes a distinct clinical phenotype driven by systemic vascular and metabolic dysregulation, necessitating an integrated approach to manage vascular risk factors.
Should not yet change practice; leaves open whether targeting cardiometabolic burden reduces incident late-life depression.
Introduction and objective: Late-life depression (LLD) is a complex mood disorder that rarely occurs in isolation, frequently co-existing with cardiometabolic multimorbidity (CMM). This comorbidity triggers a cascade of adverse consequences, including accelerated biological aging and increased mortality. The objective of this narrative review is to synthesize current knowledge on the bidirectional relationship between CMM and LLD, exploring pathophysiological mechanisms from the Vascular Depression (VaDep) hypothesis to clinical implications. Description of the state of knowledge: Epidemiological evidence indicates a strong "dose-response" relationship, where cumulative cardiometabolic burden amplifies the risk of incident depression. The review discusses the neuroimaging correlates of VaDep, particularly white matter hyperintensities, while addressing the "neuropathological paradox" observed in postmortem studies. Key pathogenic pathways identified include chronic low-grade inflammation ("inflamm-aging"), endothelial dysfunction, and the "metabolic-brain axis," specifically in type 2 diabetes. Furthermore, the analysis highlights the role of shared genetic susceptibility and the phenomenon of "joint trajectories," where physical, cognitive, and mood decline occur synchronously. Conclusions: LLD in the context of CMM constitutes a distinct clinical phenotype driven by systemic vascular and metabolic dysregulation. Current evidence necessitates a paradigm shift from isolated psychiatric management to an integrated, interdisciplinary approach. Aggressive control of vascular risk factors, potential anti-inflammatory strategies, and social prescribing are pivotal for breaking the vicious cycle of multimorbidity and improving long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Andrzejewska et al. (2025) conducted a review in Late-life depression and cardiometabolic multimorbidity. Cardiometabolic multimorbidity significantly increases the risk of late-life depression, with each additional condition elevating the risk by more than 40%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: